Multicenter study confirms low testosterone in 84 percent of lung cancer patients taking crizotinib

April 16, 2013

A previous study by the University of Colorado Cancer Center reported the common side effect of low testosterone in men treated with the recently approved lung cancer agent, crizotinib. A new study published this week in the journal Cancer confirms this finding in a multi-national sample, details the mechanism of reduced testosterone, and provides promising preliminary evidence that widely available hormone replacement therapies can alleviate this side effect in many patients.

"This was a wonderful collaboration between multiple centers confirming a side effect that had not been noted when the drug was initially approved by the FDA," says Ross Camidge, MD, PhD, investigator at the CU Cancer Center, director of the thoracic oncology clinical program at University of Colorado Hospital, and the paper's senior author.

Specifically, the study – which included researchers in the United States, Hong Kong, Italy and the UK – found that in 84 percent of men treated with crizotinib, were below the lower limit of normal. Importantly, this study also showed, for the first time, that approximately 80 percent of these men had symptoms associated with their low such as or depression.

Testosterone levels seemed to fall for two main reasons. First, the proteins and SHBG that bind testosterone in the blood and act as a storage depot for the hormone dropped rapidly with crizotinib use. Additionally, free testosterone – the functional form of the hormone that is liberated from these proteins – was also reduced, implying that in addition to challenging the body's ability to store testosterone, crizotinib also challenges the body's ability to produce it. Camidge and colleagues went on to show that when low levels are found, testosterone replacement therapy may alleviate these symptoms.

"With advances in targeted therapies and in the we can use to select who to best give these new treatments to, we're starting to see drugs being approved more quickly and based on the results from far smaller numbers of patients than ever before. That's great: it helps streamline the path of these drugs into clinics where they can benefit patients who desperately need them. However, it also puts the onus on clinicians who then start using these drugs in day-to-day practice to recognize either subtle or later onset side effects that may have been missed during the initial testing," Camidge says.

For example, he says, it's perhaps not surprising that the potential for lowered testosterone was overlooked during the lightning-fast approval process for crizotinib: "If you don't specifically ask a man about symptoms of low testosterone, unless you know the patient very well, he may not feel comfortable bringing these issues up himself," Camidge says.

Now with the possibility of low testosterone in mind, clinicians who prescribe crizotinib to their male patients will know to ask about these symptoms and to test their testosterone levels. "With each breakthrough we're really trying to put people with advanced cancer back in control of their own lives," says Camidge. "The more we can make these highly effective new treatments tolerable, the closer we are to achieving that goal."

Explore further: Testosterone therapy improves sexual interest, function in older men

Related Stories

Testosterone therapy improves sexual interest, function in older men

June 29, 2016
Older men with low libido and low testosterone levels showed more interest in sex and engaged in more sexual activity when they underwent testosterone therapy, according to a new study published in the Endocrine Society's ...

Low testosterone thresholds established for type 2 diabetes

August 25, 2016
Research into type 2 diabetes conducted by Western Sydney University has for the first time established a range of clinical thresholds for testosterone levels in men associated with developing diabetes.

Doctors urged to be cautious when treating low testosterone

August 30, 2016
Doctors have been advised to exercise caution when prescribing testosterone treatment for older men with low testosterone and a history of cardiovascular disease, according to a position statement published today in the Medical ...

Testosterone undecanoate cuts anemia in hypogonadal men

April 18, 2016
(HealthDay)—Testosterone undecanoate reduces anemia in patients with subnormal testosterone levels, according to a study published in the April issue of The Journal of Urology.

Testosterone undecanoate improves sexual function in men with type 2 diabetes

May 6, 2016
In a recent placebo-controlled study, long acting testosterone undecanoate (an ester of testosterone) improved erectile function, intercourse satisfaction, and sexual desire scores in type 2 diabetic men with severe hypogonadism, ...

New crizotinib side-effect: Reduced measures of kidney function during treatment (recovery after)

November 21, 2013
A University of Colorado Cancer Center study published today in the journal Cancer shows that using crizotinib to treat ALK positive non-small cell lung cancer (NSCLC) appears to reduce kidney function when assessed by one ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.